nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0733	0.126	CbGbCtD
Methylergometrine—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0689	0.119	CbGbCtD
Methylergometrine—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0689	0.119	CbGbCtD
Methylergometrine—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0623	0.107	CbGbCtD
Methylergometrine—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0623	0.107	CbGbCtD
Methylergometrine—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0538	0.0925	CbGbCtD
Methylergometrine—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0522	0.0898	CbGbCtD
Methylergometrine—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0472	0.0812	CbGbCtD
Methylergometrine—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0472	0.0812	CbGbCtD
Methylergometrine—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0453	0.0779	CbGbCtD
Methylergometrine—DRD1—nerve—acquired immunodeficiency syndrome	0.00854	0.114	CbGeAlD
Methylergometrine—Vasospasm—Ritonavir—acquired immunodeficiency syndrome	0.00825	0.0309	CcSEcCtD
Methylergometrine—HTR1F—nervous system—acquired immunodeficiency syndrome	0.0038	0.0508	CbGeAlD
Methylergometrine—HTR1F—central nervous system—acquired immunodeficiency syndrome	0.00366	0.049	CbGeAlD
Methylergometrine—HTR2A—nerve—acquired immunodeficiency syndrome	0.00333	0.0445	CbGeAlD
Methylergometrine—HTR1E—nervous system—acquired immunodeficiency syndrome	0.00329	0.044	CbGeAlD
Methylergometrine—HTR1E—central nervous system—acquired immunodeficiency syndrome	0.00317	0.0424	CbGeAlD
Methylergometrine—HTR1F—brain—acquired immunodeficiency syndrome	0.0029	0.0389	CbGeAlD
Methylergometrine—HTR2A—endothelium—acquired immunodeficiency syndrome	0.00283	0.0379	CbGeAlD
Methylergometrine—Cramps of lower extremities—Delavirdine—acquired immunodeficiency syndrome	0.0028	0.0105	CcSEcCtD
Methylergometrine—Thrombophlebitis—Efavirenz—acquired immunodeficiency syndrome	0.00267	0.01	CcSEcCtD
Methylergometrine—Cramps of lower extremities—Ritonavir—acquired immunodeficiency syndrome	0.00259	0.0097	CcSEcCtD
Methylergometrine—HTR2A—blood plasma—acquired immunodeficiency syndrome	0.00252	0.0337	CbGeAlD
Methylergometrine—HTR1E—brain—acquired immunodeficiency syndrome	0.00252	0.0337	CbGeAlD
Methylergometrine—Cramps of lower extremities—Saquinavir—acquired immunodeficiency syndrome	0.00249	0.00934	CcSEcCtD
Methylergometrine—Cardiac disorder—Amprenavir—acquired immunodeficiency syndrome	0.00246	0.00921	CcSEcCtD
Methylergometrine—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00233	0.0312	CbGeAlD
Methylergometrine—Thrombophlebitis—Saquinavir—acquired immunodeficiency syndrome	0.00227	0.00853	CcSEcCtD
Methylergometrine—HTR2B—skin of body—acquired immunodeficiency syndrome	0.00227	0.0303	CbGeAlD
Methylergometrine—Haematuria—Stavudine—acquired immunodeficiency syndrome	0.00222	0.00834	CcSEcCtD
Methylergometrine—Sweating increased—Zidovudine—acquired immunodeficiency syndrome	0.00222	0.0083	CcSEcCtD
Methylergometrine—Angina pectoris—Indinavir—acquired immunodeficiency syndrome	0.00206	0.00772	CcSEcCtD
Methylergometrine—Cerebrovascular accident—Saquinavir—acquired immunodeficiency syndrome	0.00201	0.00753	CcSEcCtD
Methylergometrine—Sweating increased—Efavirenz—acquired immunodeficiency syndrome	0.00195	0.0073	CcSEcCtD
Methylergometrine—Haematuria—Zidovudine—acquired immunodeficiency syndrome	0.00193	0.00725	CcSEcCtD
Methylergometrine—DRD1—nervous system—acquired immunodeficiency syndrome	0.00192	0.0257	CbGeAlD
Methylergometrine—Sweating increased—Delavirdine—acquired immunodeficiency syndrome	0.00186	0.00698	CcSEcCtD
Methylergometrine—DRD1—central nervous system—acquired immunodeficiency syndrome	0.00185	0.0248	CbGeAlD
Methylergometrine—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.00184	0.00691	CcSEcCtD
Methylergometrine—HTR2B—digestive system—acquired immunodeficiency syndrome	0.00181	0.0243	CbGeAlD
Methylergometrine—Haematuria—Indinavir—acquired immunodeficiency syndrome	0.0018	0.00674	CcSEcCtD
Methylergometrine—HTR2C—spinal cord—acquired immunodeficiency syndrome	0.00177	0.0237	CbGeAlD
Methylergometrine—Muscle spasms—Nelfinavir—acquired immunodeficiency syndrome	0.00176	0.00659	CcSEcCtD
Methylergometrine—HTR2B—blood—acquired immunodeficiency syndrome	0.00173	0.0231	CbGeAlD
Methylergometrine—Anaphylactic shock—Didanosine—acquired immunodeficiency syndrome	0.00171	0.00642	CcSEcCtD
Methylergometrine—Haematuria—Efavirenz—acquired immunodeficiency syndrome	0.0017	0.00637	CcSEcCtD
Methylergometrine—Cardiac disorder—Zidovudine—acquired immunodeficiency syndrome	0.00169	0.00633	CcSEcCtD
Methylergometrine—Paraesthesia—Amprenavir—acquired immunodeficiency syndrome	0.00169	0.00633	CcSEcCtD
Methylergometrine—Sweating increased—Saquinavir—acquired immunodeficiency syndrome	0.00166	0.00621	CcSEcCtD
Methylergometrine—Haematuria—Delavirdine—acquired immunodeficiency syndrome	0.00163	0.00609	CcSEcCtD
Methylergometrine—HTR2B—vagina—acquired immunodeficiency syndrome	0.0016	0.0214	CbGeAlD
Methylergometrine—Hallucination—Efavirenz—acquired immunodeficiency syndrome	0.00159	0.00597	CcSEcCtD
Methylergometrine—Convulsion—Nelfinavir—acquired immunodeficiency syndrome	0.00158	0.00594	CcSEcCtD
Methylergometrine—Sweating increased—Lamivudine—acquired immunodeficiency syndrome	0.00158	0.00593	CcSEcCtD
Methylergometrine—Bradycardia—Delavirdine—acquired immunodeficiency syndrome	0.00156	0.00584	CcSEcCtD
Methylergometrine—Convulsion—Abacavir—acquired immunodeficiency syndrome	0.00156	0.00583	CcSEcCtD
Methylergometrine—Anaphylactic shock—Nevirapine—acquired immunodeficiency syndrome	0.00154	0.00578	CcSEcCtD
Methylergometrine—Paraesthesia—Didanosine—acquired immunodeficiency syndrome	0.00154	0.00577	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Amprenavir—acquired immunodeficiency syndrome	0.00154	0.00576	CcSEcCtD
Methylergometrine—Muscle spasms—Zidovudine—acquired immunodeficiency syndrome	0.00152	0.00571	CcSEcCtD
Methylergometrine—Hallucination—Delavirdine—acquired immunodeficiency syndrome	0.00152	0.00571	CcSEcCtD
Methylergometrine—HTR2B—lung—acquired immunodeficiency syndrome	0.00151	0.0203	CbGeAlD
Methylergometrine—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00151	0.00566	CcSEcCtD
Methylergometrine—Haematuria—Ritonavir—acquired immunodeficiency syndrome	0.0015	0.00563	CcSEcCtD
Methylergometrine—HTR2C—nervous system—acquired immunodeficiency syndrome	0.00149	0.02	CbGeAlD
Methylergometrine—Tinnitus—Efavirenz—acquired immunodeficiency syndrome	0.00149	0.00559	CcSEcCtD
Methylergometrine—Abdominal pain—Amprenavir—acquired immunodeficiency syndrome	0.00149	0.00557	CcSEcCtD
Methylergometrine—Cardiac disorder—Efavirenz—acquired immunodeficiency syndrome	0.00148	0.00556	CcSEcCtD
Methylergometrine—DRD1—brain—acquired immunodeficiency syndrome	0.00147	0.0197	CbGeAlD
Methylergometrine—Anaphylactic shock—Abacavir—acquired immunodeficiency syndrome	0.00147	0.00549	CcSEcCtD
Methylergometrine—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.00146	0.00547	CcSEcCtD
Methylergometrine—Hyperhidrosis—Nelfinavir—acquired immunodeficiency syndrome	0.00144	0.00541	CcSEcCtD
Methylergometrine—Hyperhidrosis—Stavudine—acquired immunodeficiency syndrome	0.00144	0.00539	CcSEcCtD
Methylergometrine—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.00144	0.00539	CcSEcCtD
Methylergometrine—HTR2C—central nervous system—acquired immunodeficiency syndrome	0.00144	0.0192	CbGeAlD
Methylergometrine—Tinnitus—Delavirdine—acquired immunodeficiency syndrome	0.00143	0.00535	CcSEcCtD
Methylergometrine—Muscle spasms—Indinavir—acquired immunodeficiency syndrome	0.00142	0.00531	CcSEcCtD
Methylergometrine—Hallucination—Ritonavir—acquired immunodeficiency syndrome	0.00141	0.00528	CcSEcCtD
Methylergometrine—HTR2B—nervous system—acquired immunodeficiency syndrome	0.0014	0.0188	CbGeAlD
Methylergometrine—Gastrointestinal pain—Didanosine—acquired immunodeficiency syndrome	0.0014	0.00525	CcSEcCtD
Methylergometrine—Paraesthesia—Nevirapine—acquired immunodeficiency syndrome	0.00138	0.00519	CcSEcCtD
Methylergometrine—HTR2A—retina—acquired immunodeficiency syndrome	0.00138	0.0184	CbGeAlD
Methylergometrine—Convulsion—Zidovudine—acquired immunodeficiency syndrome	0.00137	0.00515	CcSEcCtD
Methylergometrine—Hypotension—Abacavir—acquired immunodeficiency syndrome	0.00137	0.00513	CcSEcCtD
Methylergometrine—Hallucination—Saquinavir—acquired immunodeficiency syndrome	0.00136	0.00508	CcSEcCtD
Methylergometrine—Abdominal pain—Didanosine—acquired immunodeficiency syndrome	0.00135	0.00508	CcSEcCtD
Methylergometrine—HTR2B—central nervous system—acquired immunodeficiency syndrome	0.00135	0.0181	CbGeAlD
Methylergometrine—Chest pain—Zidovudine—acquired immunodeficiency syndrome	0.00135	0.00506	CcSEcCtD
Methylergometrine—Paraesthesia—Nelfinavir—acquired immunodeficiency syndrome	0.00134	0.00502	CcSEcCtD
Methylergometrine—Paraesthesia—Stavudine—acquired immunodeficiency syndrome	0.00134	0.00501	CcSEcCtD
Methylergometrine—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.00133	0.00499	CcSEcCtD
Methylergometrine—Tinnitus—Ritonavir—acquired immunodeficiency syndrome	0.00132	0.00495	CcSEcCtD
Methylergometrine—Paraesthesia—Abacavir—acquired immunodeficiency syndrome	0.00132	0.00493	CcSEcCtD
Methylergometrine—Cardiac disorder—Ritonavir—acquired immunodeficiency syndrome	0.00131	0.00492	CcSEcCtD
Methylergometrine—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.00131	0.0049	CcSEcCtD
Methylergometrine—Palpitations—Indinavir—acquired immunodeficiency syndrome	0.0013	0.00488	CcSEcCtD
Methylergometrine—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.00129	0.00485	CcSEcCtD
Methylergometrine—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.00129	0.00482	CcSEcCtD
Methylergometrine—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.00128	0.0048	CcSEcCtD
Methylergometrine—Tinnitus—Saquinavir—acquired immunodeficiency syndrome	0.00127	0.00476	CcSEcCtD
Methylergometrine—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.00127	0.00475	CcSEcCtD
Methylergometrine—Cardiac disorder—Saquinavir—acquired immunodeficiency syndrome	0.00126	0.00474	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.00126	0.00472	CcSEcCtD
Methylergometrine—Chest pain—Indinavir—acquired immunodeficiency syndrome	0.00125	0.0047	CcSEcCtD
Methylergometrine—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.00125	0.00469	CcSEcCtD
Methylergometrine—Palpitations—Efavirenz—acquired immunodeficiency syndrome	0.00123	0.00461	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00122	0.00457	CcSEcCtD
Methylergometrine—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.00122	0.00457	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.00122	0.00456	CcSEcCtD
Methylergometrine—Convulsion—Efavirenz—acquired immunodeficiency syndrome	0.00121	0.00452	CcSEcCtD
Methylergometrine—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.0012	0.00451	CcSEcCtD
Methylergometrine—Hypertension—Efavirenz—acquired immunodeficiency syndrome	0.0012	0.00451	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.0012	0.00449	CcSEcCtD
Methylergometrine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.0012	0.00448	CcSEcCtD
Methylergometrine—Chest pain—Efavirenz—acquired immunodeficiency syndrome	0.00119	0.00444	CcSEcCtD
Methylergometrine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00119	0.00444	CcSEcCtD
Methylergometrine—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.00118	0.00444	CcSEcCtD
Methylergometrine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00118	0.00444	CcSEcCtD
Methylergometrine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00118	0.00442	CcSEcCtD
Methylergometrine—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00118	0.00442	CcSEcCtD
Methylergometrine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00118	0.00441	CcSEcCtD
Methylergometrine—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.00118	0.00441	CcSEcCtD
Methylergometrine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.00118	0.00441	CcSEcCtD
Methylergometrine—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.00117	0.0044	CcSEcCtD
Methylergometrine—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.00116	0.00436	CcSEcCtD
Methylergometrine—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.00116	0.00435	CcSEcCtD
Methylergometrine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.00116	0.00434	CcSEcCtD
Methylergometrine—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.00115	0.00432	CcSEcCtD
Methylergometrine—Hypertension—Delavirdine—acquired immunodeficiency syndrome	0.00115	0.00431	CcSEcCtD
Methylergometrine—HTR2C—brain—acquired immunodeficiency syndrome	0.00114	0.0153	CbGeAlD
Methylergometrine—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.00114	0.00427	CcSEcCtD
Methylergometrine—Chest pain—Delavirdine—acquired immunodeficiency syndrome	0.00113	0.00425	CcSEcCtD
Methylergometrine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00112	0.00419	CcSEcCtD
Methylergometrine—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00111	0.00418	CcSEcCtD
Methylergometrine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00111	0.00416	CcSEcCtD
Methylergometrine—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.0011	0.00412	CcSEcCtD
Methylergometrine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00109	0.00408	CcSEcCtD
Methylergometrine—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.00109	0.00408	CcSEcCtD
Methylergometrine—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.00109	0.00408	CcSEcCtD
Methylergometrine—Rash—Didanosine—acquired immunodeficiency syndrome	0.00108	0.00405	CcSEcCtD
Methylergometrine—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.00108	0.00405	CcSEcCtD
Methylergometrine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00108	0.00405	CcSEcCtD
Methylergometrine—Headache—Didanosine—acquired immunodeficiency syndrome	0.00107	0.00402	CcSEcCtD
Methylergometrine—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.00107	0.00402	CcSEcCtD
Methylergometrine—HTR2B—brain—acquired immunodeficiency syndrome	0.00107	0.0143	CbGeAlD
Methylergometrine—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.00107	0.004	CcSEcCtD
Methylergometrine—Hypertension—Ritonavir—acquired immunodeficiency syndrome	0.00106	0.00399	CcSEcCtD
Methylergometrine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00106	0.00398	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.00106	0.00396	CcSEcCtD
Methylergometrine—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.00105	0.00395	CcSEcCtD
Methylergometrine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.00105	0.00394	CcSEcCtD
Methylergometrine—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.00105	0.00393	CcSEcCtD
Methylergometrine—HTR2B—lymph node—acquired immunodeficiency syndrome	0.00104	0.0139	CbGeAlD
Methylergometrine—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.00103	0.00385	CcSEcCtD
Methylergometrine—Hypertension—Saquinavir—acquired immunodeficiency syndrome	0.00102	0.00384	CcSEcCtD
Methylergometrine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.00102	0.00383	CcSEcCtD
Methylergometrine—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.00102	0.00383	CcSEcCtD
Methylergometrine—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00102	0.00382	CcSEcCtD
Methylergometrine—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00102	0.00382	CcSEcCtD
Methylergometrine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00102	0.00382	CcSEcCtD
Methylergometrine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.00102	0.00381	CcSEcCtD
Methylergometrine—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.00101	0.0038	CcSEcCtD
Methylergometrine—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.00101	0.00378	CcSEcCtD
Methylergometrine—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.001	0.00376	CcSEcCtD
Methylergometrine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000987	0.0037	CcSEcCtD
Methylergometrine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000986	0.0037	CcSEcCtD
Methylergometrine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000984	0.00369	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000984	0.00369	CcSEcCtD
Methylergometrine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000981	0.00368	CcSEcCtD
Methylergometrine—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.00098	0.00367	CcSEcCtD
Methylergometrine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00098	0.00367	CcSEcCtD
Methylergometrine—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000976	0.00366	CcSEcCtD
Methylergometrine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000972	0.00364	CcSEcCtD
Methylergometrine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000972	0.00364	CcSEcCtD
Methylergometrine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000971	0.00364	CcSEcCtD
Methylergometrine—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000969	0.00363	CcSEcCtD
Methylergometrine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000969	0.00363	CcSEcCtD
Methylergometrine—HTR2A—digestive system—acquired immunodeficiency syndrome	0.000968	0.013	CbGeAlD
Methylergometrine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000966	0.00362	CcSEcCtD
Methylergometrine—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000963	0.00361	CcSEcCtD
Methylergometrine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000951	0.00356	CcSEcCtD
Methylergometrine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000949	0.00356	CcSEcCtD
Methylergometrine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000949	0.00356	CcSEcCtD
Methylergometrine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000946	0.00355	CcSEcCtD
Methylergometrine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000941	0.00353	CcSEcCtD
Methylergometrine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00094	0.00352	CcSEcCtD
Methylergometrine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.00094	0.00352	CcSEcCtD
Methylergometrine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000938	0.00352	CcSEcCtD
Methylergometrine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000937	0.00351	CcSEcCtD
Methylergometrine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000936	0.00351	CcSEcCtD
Methylergometrine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000935	0.0035	CcSEcCtD
Methylergometrine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000932	0.00349	CcSEcCtD
Methylergometrine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000932	0.00349	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000929	0.00348	CcSEcCtD
Methylergometrine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000924	0.00346	CcSEcCtD
Methylergometrine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000923	0.00346	CcSEcCtD
Methylergometrine—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000923	0.00346	CcSEcCtD
Methylergometrine—HTR2A—blood—acquired immunodeficiency syndrome	0.000922	0.0123	CbGeAlD
Methylergometrine—Headache—Abacavir—acquired immunodeficiency syndrome	0.000918	0.00344	CcSEcCtD
Methylergometrine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000915	0.00343	CcSEcCtD
Methylergometrine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000905	0.00339	CcSEcCtD
Methylergometrine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000904	0.00339	CcSEcCtD
Methylergometrine—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000903	0.00338	CcSEcCtD
Methylergometrine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000898	0.00337	CcSEcCtD
Methylergometrine—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000896	0.00336	CcSEcCtD
Methylergometrine—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000896	0.012	CbGeAlD
Methylergometrine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000893	0.00335	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000889	0.00333	CcSEcCtD
Methylergometrine—HTR2A—spinal cord—acquired immunodeficiency syndrome	0.000889	0.0119	CbGeAlD
Methylergometrine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000887	0.00332	CcSEcCtD
Methylergometrine—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000885	0.00332	CcSEcCtD
Methylergometrine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000884	0.00331	CcSEcCtD
Methylergometrine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000871	0.00326	CcSEcCtD
Methylergometrine—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000869	0.00326	CcSEcCtD
Methylergometrine—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000863	0.00323	CcSEcCtD
Methylergometrine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000863	0.00323	CcSEcCtD
Methylergometrine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00086	0.00322	CcSEcCtD
Methylergometrine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000855	0.00321	CcSEcCtD
Methylergometrine—HTR2A—vagina—acquired immunodeficiency syndrome	0.000855	0.0114	CbGeAlD
Methylergometrine—CYP3A4—blood—acquired immunodeficiency syndrome	0.000854	0.0114	CbGeAlD
Methylergometrine—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000829	0.00311	CcSEcCtD
Methylergometrine—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000823	0.00309	CcSEcCtD
Methylergometrine—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000823	0.00308	CcSEcCtD
Methylergometrine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000822	0.00308	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000822	0.00308	CcSEcCtD
Methylergometrine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000816	0.00306	CcSEcCtD
Methylergometrine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000815	0.00305	CcSEcCtD
Methylergometrine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00081	0.00304	CcSEcCtD
Methylergometrine—HTR2A—lung—acquired immunodeficiency syndrome	0.000809	0.0108	CbGeAlD
Methylergometrine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000795	0.00298	CcSEcCtD
Methylergometrine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000795	0.00298	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000791	0.00297	CcSEcCtD
Methylergometrine—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000778	0.00291	CcSEcCtD
Methylergometrine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000768	0.00288	CcSEcCtD
Methylergometrine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000765	0.00287	CcSEcCtD
Methylergometrine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000765	0.00287	CcSEcCtD
Methylergometrine—Rash—Indinavir—acquired immunodeficiency syndrome	0.000758	0.00284	CcSEcCtD
Methylergometrine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000758	0.00284	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000755	0.00283	CcSEcCtD
Methylergometrine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000754	0.00282	CcSEcCtD
Methylergometrine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000752	0.00282	CcSEcCtD
Methylergometrine—HTR2A—nervous system—acquired immunodeficiency syndrome	0.000749	0.01	CbGeAlD
Methylergometrine—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000744	0.00279	CcSEcCtD
Methylergometrine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00073	0.00274	CcSEcCtD
Methylergometrine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000723	0.00271	CcSEcCtD
Methylergometrine—HTR2A—central nervous system—acquired immunodeficiency syndrome	0.000721	0.00965	CbGeAlD
Methylergometrine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000719	0.00269	CcSEcCtD
Methylergometrine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000717	0.00269	CcSEcCtD
Methylergometrine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000716	0.00268	CcSEcCtD
Methylergometrine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000714	0.00268	CcSEcCtD
Methylergometrine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000712	0.00267	CcSEcCtD
Methylergometrine—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000693	0.00928	CbGeAlD
Methylergometrine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000691	0.00259	CcSEcCtD
Methylergometrine—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000688	0.00258	CcSEcCtD
Methylergometrine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000686	0.00257	CcSEcCtD
Methylergometrine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000685	0.00257	CcSEcCtD
Methylergometrine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000681	0.00255	CcSEcCtD
Methylergometrine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000675	0.00253	CcSEcCtD
Methylergometrine—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000667	0.00893	CbGeAlD
Methylergometrine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000665	0.00249	CcSEcCtD
Methylergometrine—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000662	0.00248	CcSEcCtD
Methylergometrine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000646	0.00242	CcSEcCtD
Methylergometrine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00064	0.0024	CcSEcCtD
Methylergometrine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000639	0.0024	CcSEcCtD
Methylergometrine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000634	0.00238	CcSEcCtD
Methylergometrine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000633	0.00237	CcSEcCtD
Methylergometrine—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000632	0.00237	CcSEcCtD
Methylergometrine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00063	0.00236	CcSEcCtD
Methylergometrine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000615	0.00231	CcSEcCtD
Methylergometrine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000611	0.00229	CcSEcCtD
Methylergometrine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00061	0.00229	CcSEcCtD
Methylergometrine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00061	0.00228	CcSEcCtD
Methylergometrine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000606	0.00227	CcSEcCtD
Methylergometrine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000597	0.00224	CcSEcCtD
Methylergometrine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000587	0.0022	CcSEcCtD
Methylergometrine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000582	0.00218	CcSEcCtD
Methylergometrine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000582	0.00218	CcSEcCtD
Methylergometrine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000578	0.00217	CcSEcCtD
Methylergometrine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000575	0.00215	CcSEcCtD
Methylergometrine—HTR2A—brain—acquired immunodeficiency syndrome	0.000572	0.00766	CbGeAlD
Methylergometrine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000548	0.00206	CcSEcCtD
Methylergometrine—DRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000266	0.00344	CbGpPWpGaD
Methylergometrine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000265	0.00344	CbGpPWpGaD
Methylergometrine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000265	0.00343	CbGpPWpGaD
Methylergometrine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000265	0.00343	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000263	0.0034	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000261	0.00338	CbGpPWpGaD
Methylergometrine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000251	0.00326	CbGpPWpGaD
Methylergometrine—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00025	0.00324	CbGpPWpGaD
Methylergometrine—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00025	0.00324	CbGpPWpGaD
Methylergometrine—HTR2C—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00025	0.00323	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000246	0.00319	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000246	0.00318	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000243	0.00315	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000237	0.00307	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000235	0.00305	CbGpPWpGaD
Methylergometrine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000231	0.00298	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000228	0.00295	CbGpPWpGaD
Methylergometrine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000227	0.00294	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000224	0.0029	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000222	0.00287	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000218	0.00283	CbGpPWpGaD
Methylergometrine—HTR2A—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000217	0.00281	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000215	0.00278	CbGpPWpGaD
Methylergometrine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000214	0.00277	CbGpPWpGaD
Methylergometrine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000214	0.00277	CbGpPWpGaD
Methylergometrine—HTR2B—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000212	0.00275	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000207	0.00268	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000206	0.00267	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000202	0.00262	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000202	0.00261	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000202	0.00261	CbGpPWpGaD
Methylergometrine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000202	0.00261	CbGpPWpGaD
Methylergometrine—DRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.0002	0.00259	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000198	0.00256	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000198	0.00256	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000197	0.00256	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000197	0.00255	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000195	0.00253	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000195	0.00252	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000194	0.00251	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000194	0.00251	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000192	0.00249	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000191	0.00248	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00019	0.00246	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00019	0.00246	CbGpPWpGaD
Methylergometrine—DRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00019	0.00246	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000187	0.00243	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000187	0.00242	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000187	0.00242	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000186	0.00241	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000186	0.0024	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000186	0.0024	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000183	0.00237	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000183	0.00237	CbGpPWpGaD
Methylergometrine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000182	0.00235	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000181	0.00235	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000179	0.00232	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000178	0.00231	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000177	0.00229	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000176	0.00228	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000176	0.00228	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000173	0.00224	CbGpPWpGaD
Methylergometrine—DRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000171	0.00222	CbGpPWpGaD
Methylergometrine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000171	0.00221	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000169	0.00219	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000168	0.00218	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000166	0.00215	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000166	0.00215	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000166	0.00215	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000163	0.00211	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000163	0.00211	CbGpPWpGaD
Methylergometrine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000163	0.00211	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000159	0.00206	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000155	0.00201	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000154	0.00199	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00015	0.00195	CbGpPWpGaD
Methylergometrine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000149	0.00192	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000148	0.00191	CbGpPWpGaD
Methylergometrine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000147	0.0019	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000145	0.00188	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000145	0.00187	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000144	0.00186	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000141	0.00183	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000141	0.00183	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000141	0.00183	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000139	0.0018	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000138	0.00179	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000138	0.00179	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000137	0.00177	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000135	0.00174	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000134	0.00173	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000133	0.00172	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000132	0.00171	CbGpPWpGaD
Methylergometrine—DRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00013	0.00169	CbGpPWpGaD
Methylergometrine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000127	0.00165	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000126	0.00164	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000125	0.00162	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000125	0.00162	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000124	0.00161	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000124	0.0016	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000122	0.00158	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000122	0.00158	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000121	0.00157	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000121	0.00156	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000116	0.00151	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000116	0.00151	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000115	0.00149	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000115	0.00149	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000114	0.00148	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000114	0.00148	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000114	0.00148	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000114	0.00147	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000112	0.00145	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000111	0.00143	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00011	0.00143	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00011	0.00142	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00011	0.00142	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000108	0.00139	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000108	0.00139	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000108	0.00139	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000105	0.00136	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000104	0.00135	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000104	0.00135	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000104	0.00135	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000104	0.00135	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000104	0.00134	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000104	0.00134	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	9.93e-05	0.00129	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	9.83e-05	0.00127	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.81e-05	0.00127	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.81e-05	0.00127	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	9.79e-05	0.00127	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	9.77e-05	0.00126	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	9.77e-05	0.00126	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	9.69e-05	0.00125	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.4e-05	0.00122	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.4e-05	0.00122	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	9.35e-05	0.00121	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.2e-05	0.00119	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.2e-05	0.00119	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.89e-05	0.00115	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.68e-05	0.00112	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	8.55e-05	0.00111	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.53e-05	0.00111	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.5e-05	0.0011	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.5e-05	0.0011	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.36e-05	0.00108	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.36e-05	0.00108	CbGpPWpGaD
Methylergometrine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	8.33e-05	0.00108	CbGpPWpGaD
Methylergometrine—DRD1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	8.29e-05	0.00107	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	8.18e-05	0.00106	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.16e-05	0.00106	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.16e-05	0.00106	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	8.06e-05	0.00104	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.99e-05	0.00103	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.99e-05	0.00103	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.91e-05	0.00102	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.88e-05	0.00102	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.82e-05	0.00101	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.79e-05	0.00101	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.76e-05	0.00101	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	7.72e-05	0.000999	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.68e-05	0.000994	CbGpPWpGaD
Methylergometrine—HTR2A—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	7.54e-05	0.000977	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.46e-05	0.000967	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	7.43e-05	0.000962	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.38e-05	0.000956	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	7.37e-05	0.000955	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	7.35e-05	0.000952	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	7.32e-05	0.000948	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.26e-05	0.00094	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.26e-05	0.00094	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	7.24e-05	0.000938	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.2e-05	0.000932	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	7.13e-05	0.000923	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.1e-05	0.000919	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7e-05	0.000906	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.97e-05	0.000903	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.9e-05	0.000893	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.79e-05	0.000879	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.73e-05	0.000871	CbGpPWpGaD
Methylergometrine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	6.72e-05	0.00087	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	6.69e-05	0.000867	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.58e-05	0.000852	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.51e-05	0.000843	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.36e-05	0.000823	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.31e-05	0.000817	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.26e-05	0.000811	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.14e-05	0.000795	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.12e-05	0.000792	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.12e-05	0.000792	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.08e-05	0.000787	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.99e-05	0.000775	CbGpPWpGaD
Methylergometrine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	5.84e-05	0.000756	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.81e-05	0.000752	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.77e-05	0.000747	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.77e-05	0.000747	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.73e-05	0.000742	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	5.56e-05	0.000721	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.52e-05	0.000715	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.48e-05	0.000709	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.44e-05	0.000704	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.25e-05	0.00068	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.04e-05	0.000653	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.97e-05	0.000644	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.94e-05	0.000639	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.94e-05	0.000639	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	4.73e-05	0.000613	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.65e-05	0.000603	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.58e-05	0.000594	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.56e-05	0.00059	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.52e-05	0.000585	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.39e-05	0.000568	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.32e-05	0.00056	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.29e-05	0.000555	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.29e-05	0.000555	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.26e-05	0.000552	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.19e-05	0.000543	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.12e-05	0.000533	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.1e-05	0.000531	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	4.1e-05	0.000531	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.95e-05	0.000512	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.89e-05	0.000503	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.87e-05	0.000501	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.87e-05	0.000501	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.76e-05	0.000486	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.7e-05	0.000479	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.64e-05	0.000472	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.38e-05	0.000438	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.31e-05	0.000428	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.26e-05	0.000422	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.21e-05	0.000416	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.16e-05	0.00041	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.94e-05	0.00038	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.87e-05	0.000372	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.42e-05	0.000314	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.42e-05	0.000314	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.41e-05	0.000312	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.28e-05	0.000296	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.28e-05	0.000296	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.27e-05	0.000294	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.95e-05	0.000253	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.94e-05	0.000252	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.7e-05	0.00022	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.69e-05	0.000219	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.42e-05	0.000184	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.34e-05	0.000174	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.15e-05	0.000149	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.98e-06	0.000129	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	9.7e-06	0.000126	CbGpPWpGaD
